{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T01:58:02Z","timestamp":1766023082763,"version":"3.48.0"},"reference-count":26,"publisher":"e-Century Publishing Corporation","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am J Nucl Med Mol Imaging"],"DOI":"10.62347\/wtkq3953","type":"journal-article","created":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T02:30:01Z","timestamp":1715135401000},"page":"41-47","source":"Crossref","is-referenced-by-count":1,"title":["Poly(ADP-ribose) polymerase (PARP)-targeted PET imaging in non-oncology application: a pilot study in preclinical models of nonalcoholic steatohepatitis"],"prefix":"10.62347","volume":"14","author":[{"given":"Troels E","family":"Jeppesen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"48694","published-online":{"date-parts":[[2024]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1001\/jama.2020.2298","article-title":"Nonalcoholic steatohepatitis: a review","volume":"323","author":"Sheka","year":"2020","unstructured":"Sheka AC, Adeyi O, Thompson J, Hameed B, Crawford PA and Ikramuddin S. Nonalcoholic steatohepatitis: a review. JAMA 2020; 323: 1175-1183.","journal-title":"JAMA"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.3390\/cells9041005","article-title":"Noninvasive diagnosis of NAFLD and NASH","volume":"9","author":"Piazzolla","year":"2020","unstructured":"Piazzolla VA and Mangia A. Noninvasive diagnosis of NAFLD and NASH. Cells 2020; 9: 1005.","journal-title":"Cells"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1002\/hep.32545","article-title":"The steatosis-associated fibrosis estimator (SAFE) score: a tool to detect low-risk NAFLD in primary care","volume":"77","author":"Sripongpun","year":"2023","unstructured":"Sripongpun P, Kim WR, Mannalithara A, Charu V, Vidovszky A, Asch S, Desai M, Kim SH and Kwong AJ. The steatosis-associated fibrosis estimator (SAFE) score: a tool to detect low-risk NAFLD in primary care. Hepatology 2023; 77: 256-267.","journal-title":"Hepatology"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1111\/j.1365-2036.2010.04556.x","article-title":"Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis","volume":"33","author":"JK","year":"2011","unstructured":"Dowman JK, Tomlinson JW and Newsome PN. Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2011; 33: 525-540.","journal-title":"Aliment Pharmacol Ther"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1021\/cr5004248","article-title":"New facets in the regulation of gene expression by ADP-ribosylation and poly(ADP-ribose) polymerases","volume":"115","author":"KW","year":"2015","unstructured":"Ryu KW, Kim DS and Kraus WL. New facets in the regulation of gene expression by ADP-ribosylation and poly(ADP-ribose) polymerases. Chem Rev 2015; 115: 2453-2481.","journal-title":"Chem Rev"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1093\/annonc\/mdq322","article-title":"A review of PARP inhibitors: from bench to bedside","volume":"22","author":"Underhill","year":"2011","unstructured":"Underhill C, Toulmonde M and Bonnefoi H. A review of PARP inhibitors: from bench to bedside. Ann Oncol 2011; 22: 268-279.","journal-title":"Ann Oncol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1093\/annonc\/mdz192","article-title":"A decade of clinical development of PARP inhibitors in perspective","volume":"30","author":"Mateo","year":"2019","unstructured":"Mateo J, Lord CJ, Serra V, Tutt A, Balmaña J, Castroviejo-Bermejo M, Cruz C, Oaknin A, Kaye SB and de Bono JS. A decade of clinical development of PARP inhibitors in perspective. Ann Oncol 2019; 30: 1437-1447.","journal-title":"Ann Oncol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/nrgastro.2016.186","article-title":"Steatohepatitis: PARP inhibition protective against alcoholic steatohepatitis and NASH","volume":"14","author":"Ray","year":"2017","unstructured":"Ray K. Steatohepatitis: PARP inhibition protective against alcoholic steatohepatitis and NASH. Nat Rev Gastroenterol Hepatol 2017; 14: 3.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.jhep.2016.10.023","article-title":"PARP inhibition protects against alcoholic and non-alcoholic steatohepatitis","volume":"66","author":"Mukhopadhyay","year":"2017","unstructured":"Mukhopadhyay P, Horváth B, Rajesh M, Varga ZV, Gariani K, Ryu D, Cao Z, Holovac E, Park O, Zhou Z, Xu MJ, Wang W, Godlewski G, Paloczi J, Nemeth BT, Persidsky Y, Liaudet L, Haskó G, Bai P, Boulares AH, Auwerx J, Gao B and Pacher P. PARP inhibition protects against alcoholic and non-alcoholic steatohepatitis. J Hepatol 2017; 66: 589-600.","journal-title":"J Hepatol"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Lee HS, Schwarz SW, Schubert EK, Chen DL, Doot RK, Makvandi M, Lin LL, McDonald ES, Mankoff DA and Mach RH. The development of (18)F fluorthanatrace: a PET radiotracer for imaging poly (ADP-Ribose) polymerase-1. Radiol Imaging Cancer 2022; 4: e210070.","DOI":"10.1148\/rycan.210070"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"3110","DOI":"10.1158\/1078-0432.CCR-19-3484","article-title":"Safety and feasibility of PARP1\/2 imaging with (18)F-PARPi in patients with head and neck cancer","volume":"26","author":"Sch&#xF6","year":"2020","unstructured":"Schöder H, França PDS, Nakajima R, Burnazi E, Roberts S, Brand C, Grkovski M, Mauguen A, Dunphy MP, Ghossein RA, Lyashchenko SK, Lewis JS, O’Donoghue JA, Ganly I, Patel SG, Lee NY and Reiner T. Safety and feasibility of PARP1\/2 imaging with (18)F-PARPi in patients with head and neck cancer. Clin Cancer Res 2020; 26: 3110-3116.","journal-title":"Clin Cancer Res"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1062432","DOI":"10.3389\/fmed.2022.1062432","article-title":"Poly (ADP-ribose) polymerases as PET imaging targets for central nervous system diseases","volume":"9","author":"Tong","year":"2022","unstructured":"Tong J, Chen B, Tan PW, Kurpiewski S and Cai Z. Poly (ADP-ribose) polymerases as PET imaging targets for central nervous system diseases. Front Med (Lausanne) 2022; 9: 1062432.","journal-title":"Front Med (Lausanne)"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"3472","DOI":"10.1016\/j.bmcl.2017.05.077","article-title":"Initial evaluation of Cu-64 labeled PARPi-DOTA PET imaging in mice with mesothelioma","volume":"27","author":"Huang","year":"2017","unstructured":"Huang T, Hu P, Banizs AB and He J. Initial evaluation of Cu-64 labeled PARPi-DOTA PET imaging in mice with mesothelioma. Bioorg Med Chem Lett 2017; 27: 3472-3476.","journal-title":"Bioorg Med Chem Lett"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"933","DOI":"10.2174\/138161207780414241","article-title":"Poly(ADP-ribose) polymerase inhibitors: new pharmacological functions and potential clinical implications","volume":"13","author":"Lastra CA","year":"2007","unstructured":"de la Lastra CA, Villegas I and Sánchez-Fidalgo S. Poly(ADP-ribose) polymerase inhibitors: new pharmacological functions and potential clinical implications. Curr Pharm Des 2007; 13: 933-962.","journal-title":"Curr Pharm Des"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"35767","DOI":"10.1074\/jbc.M507075200","article-title":"Pivotal role of Akt activation in mitochondrial protection and cell survival by poly(ADP-ribose)polymerase-1 inhibition in oxidative stress","volume":"280","author":"Tapodi","year":"2005","unstructured":"Tapodi A, Debreceni B, Hanto K, Bognar Z, Wittmann I, Gallyas F Jr, Varbiro G and Sumegi B. Pivotal role of Akt activation in mitochondrial protection and cell survival by poly(ADP-ribose)polymerase-1 inhibition in oxidative stress. J Biol Chem 2005; 280: 35767-35775.","journal-title":"J Biol Chem"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.jhep.2016.08.024","article-title":"Inhibiting poly ADP-ribosylation increases fatty acid oxidation and protects against fatty liver disease","volume":"66","author":"Gariani","year":"2017","unstructured":"Gariani K, Ryu D, Menzies KJ, Yi HS, Stein S, Zhang H, Perino A, Lemos V, Katsyuba E, Jha P, Vijgen S, Rubbia-Brandt L, Kim YK, Kim JT, Kim KS, Shong M, Schoonjans K and Auwerx J. Inhibiting poly ADP-ribosylation increases fatty acid oxidation and protects against fatty liver disease. J Hepatol 2017; 66: 132-141.","journal-title":"J Hepatol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1016\/j.jhep.2016.11.020","article-title":"PARP1-mediated PPARα poly(ADP-ribosyl)ation suppresses fatty acid oxidation in non-alcoholic fatty liver disease","volume":"66","author":"Huang","year":"2017","unstructured":"Huang K, Du M, Tan X, Yang L, Li X, Jiang Y, Wang C, Zhang F, Zhu F, Cheng M, Yang Q, Yu L, Wang L, Huang D and Huang K. PARP1-mediated PPARα poly(ADP-ribosyl)ation suppresses fatty acid oxidation in non-alcoholic fatty liver disease. J Hepatol 2017; 66: 962-977.","journal-title":"J Hepatol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1002\/hep.26763","article-title":"Poly (ADP-ribose) polymerase-1 is a key mediator of liver inflammation and fibrosis","volume":"59","author":"Mukhopadhyay","year":"2014","unstructured":"Mukhopadhyay P, Rajesh M, Cao Z, Horváth B, Park O, Wang H, Erdelyi K, Holovac E, Wang Y, Liaudet L, Hamdaoui N, Lafdil F, Haskó G, Szabo C, Boulares AH, Gao B and Pacher P. Poly (ADP-ribose) polymerase-1 is a key mediator of liver inflammation and fibrosis. Hepatology 2014; 59: 1998-2009.","journal-title":"Hepatology"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1016\/j.bmc.2014.01.019","article-title":"Synthesis, [18F] radiolabeling, and evaluation of poly (ADP-ribose) polymerase-1 (PARP-1) inhibitors for in vivo imaging of PARP-1 using positron emission tomography","volume":"22","author":"Zhou","year":"2014","unstructured":"Zhou D, Chu W, Xu J, Jones LA, Peng X, Li S, Chen DL and Mach RH. Synthesis, [18F] radiolabeling, and evaluation of poly (ADP-ribose) polymerase-1 (PARP-1) inhibitors for in vivo imaging of PARP-1 using positron emission tomography. Bioorg Med Chem 2014; 22: 1700-1707.","journal-title":"Bioorg Med Chem"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"2116","DOI":"10.1172\/JCI97992","article-title":"A PET imaging agent for evaluating PARP-1 expression in ovarian cancer","volume":"128","author":"Makvandi","year":"2018","unstructured":"Makvandi M, Pantel A, Schwartz L, Schubert E, Xu K, Hsieh CJ, Hou C, Kim H, Weng CC, Winters H, Doot R, Farwell MD, Pryma DA, Greenberg RA, Mankoff DA, Simpkins F, Mach RH and Lin LL. A PET imaging agent for evaluating PARP-1 expression in ovarian cancer. J Clin Invest 2018; 128: 2116-2126.","journal-title":"J Clin Invest"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"765","DOI":"10.2967\/jnumed.120.243287","article-title":"Molecular imaging: PARP-1 and beyond","volume":"62","author":"LN","year":"2021","unstructured":"Puentes LN, Makvandi M and Mach RH. Molecular imaging: PARP-1 and beyond. J Nucl Med 2021; 62: 765-770.","journal-title":"J Nucl Med"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"2606","DOI":"10.1007\/s00259-023-06249-6","article-title":"PET imaging of PARP expression using (68)Ga-labelled inhibitors","volume":"50","author":"Wang","year":"2023","unstructured":"Wang X, Liu W, Li K, Chen K, He S, Zhang J, Gu B, Xu X and Song S. PET imaging of PARP expression using (68)Ga-labelled inhibitors. Eur J Nucl Med Mol Imaging 2023; 50: 2606-2620.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s13550-022-00940-9","article-title":"Correlation between molar activity, injection mass and uptake of the PARP targeting radiotracer [(18)F]olaparib in mouse models of glioma","volume":"12","author":"CY","year":"2022","unstructured":"Chan CY, Hopkins SL, Guibbal F, Pacelli A, Baguña Torres J, Mosley M, Lau D, Isenegger P, Chen Z, Wilson TC, Dias G, Hueting R, Gouverneur V and Cornelissen B. Correlation between molar activity, injection mass and uptake of the PARP targeting radiotracer [(18)F]olaparib in mouse models of glioma. EJNMMI Res 2022; 12: 67.","journal-title":"EJNMMI Res"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"504","DOI":"10.2967\/jnumed.118.213223","article-title":"PET imaging of PARP expression using (18)F-olaparib","volume":"60","author":"Wilson","year":"2019","unstructured":"Wilson TC, Xavier MA, Knight J, Verhoog S, Torres JB, Mosley M, Hopkins SL, Wallington S, Allen PD, Kersemans V, Hueting R, Smart S, Gouverneur V and Cornelissen B. PET imaging of PARP expression using (18)F-olaparib. J Nucl Med 2019; 60: 504-510.","journal-title":"J Nucl Med"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.3390\/jcm9072130","article-title":"Advancements in PARP1 targeted nuclear imaging and theranostic probes","volume":"9","author":"Ambur Sankaranarayanan","year":"2020","unstructured":"Ambur Sankaranarayanan R, Kossatz S, Weber W, Beheshti M, Morgenroth A and Mottaghy FM. Advancements in PARP1 targeted nuclear imaging and theranostic probes. J Clin Med 2020; 9: 2130.","journal-title":"J Clin Med"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jhep.2020.02.018","article-title":"[(18)F]-Alfatide PET imaging of integrin αvβ3 for the non-invasive quantification of liver fibrosis","volume":"73","author":"Shao","year":"2020","unstructured":"Shao T, Chen Z, Belov V, Wang X, Rwema SH, Kumar V, Fu H, Deng X, Rong J, Yu Q, Lang L, Lin W, Josephson L, Samir AE, Chen X, Chung RT and Liang SH. [(18)F]-Alfatide PET imaging of integrin αvβ3 for the non-invasive quantification of liver fibrosis. J Hepatol 2020; 73: 161-169.","journal-title":"J Hepatol"}],"container-title":["American Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"link":[{"URL":"https:\/\/e-century.us\/files\/ajnmmi\/14\/1\/ajnmmi0155449.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T01:53:18Z","timestamp":1766022798000},"score":1,"resource":{"primary":{"URL":"https:\/\/e-century.us\/files\/ajnmmi\/14\/1\/ajnmmi0155449.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.62347\/wtkq3953","relation":{},"ISSN":["2160-8407"],"issn-type":[{"type":"electronic","value":"2160-8407"}],"subject":[],"published":{"date-parts":[[2024]]}}}